Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Intensity Interval Training in Prediabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03773731
Recruitment Status : Recruiting
First Posted : December 12, 2018
Last Update Posted : January 9, 2019
Sponsor:
Collaborators:
University of Vienna, Institute for Sport Science
Sanatorium Hera Vienna
Information provided by (Responsible Party):
Stefan Heber, Medical University of Vienna

Brief Summary:
This trial investigates if high intensity interval training is more effective than moderate intensity continuous training in suppressing platelet reactivity and hepatic fat content in prediabetic individuals.

Condition or disease Intervention/treatment Phase
Prediabetic State Behavioral: High intensity interval training (HIIT) Behavioral: Moderate intensity continuous training (MICT) Not Applicable

Detailed Description:

Background:

The prevalence of type 2 diabetes mellitus (T2DM) is rising dramatically. T2DM represents a major cause for cardiovascular disease -related mortality and morbidity and increasingly burdens healthcare systems. While the fundamental pathomechanism of T2DM is insulin resistance of muscle and adipose tissue, recent studies demonstrate that insulin resistance in T2DM also occurs in platelets. As insulin directly inhibits platelet function, this mechanism might contribute to platelet activation and platelet hyperreactivity, which were in fact detected in diabetic patients. Since (inadvertent) platelet activation is causally linked to the development of atherosclerosis and atherothrombosis, regulation of platelet function is of utmost importance. Exercise training, performed on a regular basis has been shown to reduce morbidity and mortality in sedentary and diseased populations. Furthermore, exercise training improves whole body insulin sensitivity - however, it is currently unclear, if exercise training also affects insulin sensitivity of platelets. Recently, a time-saving interval training protocol has been adapted for T2DM-patients. Since this adapted high intensity interval training (HIIT) needs a fractional time commitment of exercise training according to current guidelines, HIIT possibly represents a promising instrument to increase adherence to exercise and thereby reduce T2DM morbidity.

Aims:

The primary aim of this study is to investigate the effect of 12 weeks of HIIT vs. continuous training (CT) on platelet insulin sensitivity and platelet (hyper)reactivity in prediabetic patients.

Secondary aims are to assess the effect of HIIT and CT on whole body insulin sensitivity and fitness in prediabetic patients as well as on various parameters of platelet function and on the hepatic fat content.

Hypotheses:

Our main hypothesis is that HIIT increases platelet insulin sensitivity and thereby decreases platelet activation/reactivity in patients with prediabetes. Methods: 44 prediabetic (see inclusion criteria) patients will be enrolled in this study. Patients will randomly be assigned to a HIIT group (committed to a supervised training program) or a CT group. After initial examinations (supervised graded exercise test, platelet function tests, oral glucose tolerance test, measurement of the hepatic fat content via FibroScan®), supervised training will be performed over a period of 12 weeks. Tests performed at the beginning of the study will be repeated after the training period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Impact of High Intensity Interval Training vs. Continuous Aerobic Training on Platelet Insulin Resistance, Platelet Function and Hepatic Steatosis in Patients With Prediabetes
Actual Study Start Date : January 4, 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prediabetes

Arm Intervention/treatment
Experimental: High intensity interval training

3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:

  • 5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test
  • 30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test.
  • 10 minutes with 30% of maximal power output.
Behavioral: High intensity interval training (HIIT)
Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals

Active Comparator: Moderate intensity continuous training

3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:

  • 5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test
  • 30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output
  • 10 minutes with 30% of maximal power output.
Behavioral: Moderate intensity continuous training (MICT)
Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)




Primary Outcome Measures :
  1. EC50 (half-maximal effective concentration) of TRAP-6 (thrombin-receptor activating peptide) in terms of surface CD62P (=platelet selectin, P-selectin) expression: group differences after 12 weeks of training [ Time Frame: 12 weeks ]
  2. EC50 of insulin in terms of intraplatelet VASP (vasodilator-stimulated phosphoprotein)-phosphorylation: group differences after 12 weeks of training [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. whole body insulin sensitivity [ Time Frame: 12 weeks ]
  2. Maximal oxygen consumption [ Time Frame: 12 weeks ]
    Unit: ml/min/kg bodymass

  3. EC50 of other platelet agonists in terms of various platelet activation markers [ Time Frame: 12 weeks ]
  4. EC50 of prostacyclin in terms of intraplatelet VASP-phosphorylation [ Time Frame: 12 weeks ]
  5. Transient elastography (FibroScan®) controlled attenuation parameter (CAP) [ Time Frame: 12 weeks ]
    The controlled attenuation parameter (CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD

  6. Fatty Liver Index (FLI) [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • prediabetic (insulin-insensitive) patients
  • either fasting plasma glucose 100- 125 mg/dl or HbA1c 5.7 - 6.4
  • < 3kg bodyweight change within the last 6 months

Exclusion Criteria:

  • Any contraindications for exercise
  • resulting from anamnesis ( e.g. history of angina pectoris, peripheral arterial disease), ECG at rest or during graded exercise test, echocardiogram, echocardiography or lung function test
  • chronical joint pain that makes exercise training on bicycle ergometers impossible
  • any conditions that make the successful participation in the study unlikely
  • islet cell autoantibodies
  • Medication: insulin, thiazolidindiones, statins, antidepressants
  • Secondary diseases: History of end-stage liver or kidney disease; pronounced neuropathy or retinopathy
  • drug or alcohol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773731


Contacts
Layout table for location contacts
Contact: Ivo Volf, PhD +43 40160 ext 31421 ivo.volf@meduniwien.ac.at
Contact: Rochus Pokan, MD +43 4277 4887225 rochus.pokan@univie.ac.at

Locations
Layout table for location information
Austria
MUVienna Recruiting
Vienna, Austria, 1090
Contact: Stefan Heber, MD, PhD    0043 1 40160 ext 31425    stefan.heber@meduniwien.ac.at   
Sponsors and Collaborators
Medical University of Vienna
University of Vienna, Institute for Sport Science
Sanatorium Hera Vienna

Layout table for additonal information
Responsible Party: Stefan Heber, Dr.med.univ. Dr.rer.nat., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT03773731     History of Changes
Other Study ID Numbers: Exercise_platelet_insulin
First Posted: December 12, 2018    Key Record Dates
Last Update Posted: January 9, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Prediabetic State
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases